Pfizer Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $33.75
- Today's High:
- $34.21
- Open Price:
- $33.97
- 52W Low:
- $33.54
- 52W High:
- $53.2543
- Prev. Close:
- $33.94
- Volume:
- 14046061
Company Statistics
- Market Cap.:
- $191.62 billion
- Book Value:
- 17.541
- Revenue TTM:
- $77.94 billion
- Operating Margin TTM:
- 32.53%
- Gross Profit TTM:
- $66.23 billion
- Profit Margin:
- 27.55%
- Return on Assets TTM:
- 7.63%
- Return on Equity TTM:
- 23.07%
Company Profile
Pfizer Inc had its IPO on 2012-08-13 under the ticker symbol PFE.
The company operates in the Healthcare sector and Drug Manufacturers-General industry. Pfizer Inc has a staff strength of 83,000 employees.
Stock update
Shares of Pfizer Inc opened at $33.97 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $33.75 - $34.21, and closed at $34.15.
This is a +0.62% increase from the previous day's closing price.
A total volume of 14,046,061 shares were traded at the close of the day’s session.
In the last one week, shares of Pfizer Inc have slipped by -4.56%.
Pfizer Inc's Key Ratios
Pfizer Inc has a market cap of $191.62 billion, indicating a price to book ratio of 3.3014 and a price to sales ratio of 3.013.
In the last 12-months Pfizer Inc’s revenue was $77.94 billion with a gross profit of $66.23 billion and an EBITDA of $31.07 billion. The EBITDA ratio measures Pfizer Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Pfizer Inc’s operating margin was 32.53% while its return on assets stood at 7.63% with a return of equity of 23.07%.
In Q2, Pfizer Inc’s quarterly earnings growth was a negative -76.4% while revenue growth was a negative 54.1%.
Pfizer Inc’s PE and PEG Ratio
- Forward PE
- 10.9649
- Trailing PE
- 9.0266
- PEG
- 1.1729
Its diluted EPS in the last 12-months stands at $3.76 per share while it has a forward price to earnings multiple of 10.9649 and a PEG multiple of 1.1729. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Pfizer Inc’s profitability.
Pfizer Inc stock is trading at a EV to sales ratio of 3.0574 and a EV to EBITDA ratio of 7.7414. Its price to sales ratio in the trailing 12-months stood at 3.013.
Pfizer Inc stock pays annual dividends of $1.62 per share, indicating a yield of 4.83% and a payout ratio of 33.82%.
Balance sheet and cash flow metrics
- Total Assets
- $220.17 billion
- Total Liabilities
- $34.65 billion
- Operating Cash Flow
- $-25485000000.00
- Capital Expenditure
- $914 million
- Dividend Payout Ratio
- 33.82%
Pfizer Inc ended 2024 with $220.17 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $220.17 billion while shareholder equity stood at $99.02 billion.
Pfizer Inc ended 2024 with $1.23 billion in deferred long-term liabilities, $34.65 billion in other current liabilities, 478000000.00 in common stock, $128.80 billion in retained earnings and $51.57 billion in goodwill. Its cash balance stood at $2.63 billion and cash and short-term investments were $44.79 billion. The company’s total short-term debt was $3,985,000,000 while long-term debt stood at $61.36 billion.
Pfizer Inc’s total current assets stands at $73.35 billion while long-term investments were $15.07 billion and short-term investments were $42.15 billion. Its net receivables were $13.43 billion compared to accounts payable of $6.08 billion and inventory worth $10.31 billion.
In 2024, Pfizer Inc's operating cash flow was $-25485000000.00 while its capital expenditure stood at $914 million.
Comparatively, Pfizer Inc paid $0.34 in dividends in 2024.
Other key metrics
- Current Trading Price
- $34.15
- 52-Week High
- $53.2543
- 52-Week Low
- $33.54
- Analyst Target Price
- $44.09
Pfizer Inc stock is currently trading at $34.15 per share. It touched a 52-week high of $53.2543 and a 52-week low of $53.2543. Analysts tracking the stock have a 12-month average target price of $44.09.
Its 50-day moving average was $35.78 and 200-day moving average was $40.34 The short ratio stood at 2.15 indicating a short percent outstanding of 0%.
Around 4% of the company’s stock are held by insiders while 7076.7% are held by institutions.
Frequently Asked Questions About Pfizer Inc
Similar Industry Stocks (Drug Manufacturers-General)
Most Active
Top Gainers
Top Losers
About
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women’s health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena, and Braftovi brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc., as well as strategic partnership with CSPC Pharmaceutical Group Limited to launch a local brand of the COVID-19 oral therapeutic treatment Nirmatrelvir/Ritonavir in China, and a collaboration with Carrick Therapeutics Limited. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.